Arvinas

Arvinas

Arvinas

We are developing firstinclass protein degradation therapeutics to degrade & destroy diseasecausing proteins via the body's own protein disposal system.
Raised
$175M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$120,000,000
IPO - 2018
Team Size
1–10
Employees
Xconomy

Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance

$120,000,000 IPO
PE HUB

VC-backed Arvinas goes public

$55,000,000 Venture capital (Series C)
Venture Funding News , PE HUB

Arvinas Completes $55M Series C